An MDS Evidence-Based Review on Treatments for Huntington's Disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a rare, complex neurodegenerative disorder.
• Current HD management relies heavily on off-label treatments.
• Evidence for effective therapies in HD gene expansion carriers is limited.

Purpose of the Study:

• To systematically review and evaluate the evidence for available therapies in Huntington's disease.
• To assess the efficacy and safety of interventions for HD gene expansion carriers.
• To provide evidence-based recommendations for HD treatment.

Main Methods:

• Utilized the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
• Conducted an electronic search of CENTRAL, MEDLINE, and EMBASE databases for randomized controlled trials.
• Included 22 studies evaluating 17 interventions across 8 clinical questions, assessing risk of bias.

Main Results:

• Deutetrabenazine showed likely benefits for motor impairment, chorea, and dystonia in HD.
• Tetrabenazine demonstrated efficacy in managing chorea.
• No evidence supported disease-modifying effects or treatments for non-motor symptoms like depression or psychosis.

Conclusions:

• Therapeutic options for Huntington's disease are scarce, primarily limited to VMAT2 inhibitors for motor symptoms.
• Current evidence does not support disease-modifying treatments for HD.
• Further research is needed to identify effective therapies for the diverse manifestations of HD.